End-of-day quote
Shanghai S.E.
06:00:00 2024-04-28 pm EDT
|
5-day change
|
1st Jan Change
|
11.96
CNY
|
-0.33%
|
|
+2.93%
|
-3.78%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
20,059
|
26,868
|
24,015
|
21,061
|
23,173
|
22,325
|
-
|
-
|
Enterprise Value (EV)
1 |
20,059
|
26,868
|
24,015
|
21,061
|
23,173
|
22,325
|
22,325
|
22,325
|
P/E ratio
|
22.5
x
|
24.3
x
|
18.7
x
|
14.3
x
|
16.4
x
|
14.7
x
|
12.9
x
|
11.4
x
|
Yield
|
1.55%
|
1.08%
|
1.17%
|
1.59%
|
1.45%
|
1.55%
|
1.76%
|
1.84%
|
Capitalization / Revenue
|
1.67
x
|
1.99
x
|
1.51
x
|
1.23
x
|
1.39
x
|
1.28
x
|
1.17
x
|
1.12
x
|
EV / Revenue
|
1.67
x
|
1.99
x
|
1.51
x
|
1.23
x
|
1.39
x
|
1.28
x
|
1.17
x
|
1.12
x
|
EV / EBITDA
|
7.3
x
|
7.55
x
|
6.71
x
|
4.91
x
|
5.12
x
|
7.65
x
|
6.54
x
|
6.02
x
|
EV / FCF
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Price to Book
|
1.94
x
|
2.45
x
|
2.05
x
|
1.66
x
|
1.69
x
|
1.49
x
|
1.37
x
|
1.25
x
|
Nbr of stocks (in thousands)
|
1,938,033
|
1,931,529
|
1,870,352
|
1,865,499
|
1,864,280
|
1,866,635
|
-
|
-
|
Reference price
2 |
10.35
|
13.91
|
12.84
|
11.29
|
12.43
|
11.96
|
11.96
|
11.96
|
Announcement Date
|
4/10/20
|
3/30/21
|
3/30/22
|
4/10/23
|
4/2/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
11,980
|
13,522
|
15,904
|
17,143
|
16,646
|
17,390
|
19,014
|
19,978
|
EBITDA
1 |
2,749
|
3,559
|
3,578
|
4,285
|
4,529
|
2,918
|
3,414
|
3,711
|
EBIT
1 |
2,187
|
2,973
|
2,983
|
3,480
|
3,507
|
3,612
|
4,158
|
4,689
|
Operating Margin
|
18.26%
|
21.99%
|
18.76%
|
20.3%
|
21.07%
|
20.77%
|
21.87%
|
23.47%
|
Earnings before Tax (EBT)
1 |
2,178
|
2,950
|
2,952
|
3,456
|
3,466
|
3,587
|
4,133
|
4,651
|
Net income
1 |
894.3
|
1,120
|
1,328
|
1,503
|
1,443
|
1,518
|
1,736
|
1,954
|
Net margin
|
7.47%
|
8.29%
|
8.35%
|
8.77%
|
8.67%
|
8.73%
|
9.13%
|
9.78%
|
EPS
2 |
0.4607
|
0.5728
|
0.6858
|
0.7921
|
0.7565
|
0.8133
|
0.9300
|
1.050
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
0.1600
|
0.1500
|
0.1500
|
0.1800
|
0.1800
|
0.1850
|
0.2100
|
0.2200
|
Announcement Date
|
4/10/20
|
3/30/21
|
3/30/22
|
4/10/23
|
4/2/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
8.98%
|
10.4%
|
11.5%
|
12.2%
|
11%
|
10.3%
|
10.8%
|
10.9%
|
ROA (Net income/ Total Assets)
|
-
|
4.18%
|
4.48%
|
4.5%
|
4%
|
5.33%
|
5.57%
|
6.35%
|
Assets
1 |
-
|
26,798
|
29,630
|
33,417
|
36,047
|
28,463
|
31,190
|
30,764
|
Book Value Per Share
2 |
5.340
|
5.680
|
6.250
|
6.800
|
7.370
|
8.010
|
8.750
|
9.580
|
Cash Flow per Share
2 |
1.190
|
1.550
|
1.320
|
2.060
|
2.110
|
2.510
|
2.090
|
2.110
|
Capex
1 |
701
|
781
|
1,512
|
1,145
|
1,115
|
913
|
1,116
|
975
|
Capex / Sales
|
5.85%
|
5.78%
|
9.51%
|
6.68%
|
6.7%
|
5.25%
|
5.87%
|
4.88%
|
Announcement Date
|
4/10/20
|
3/30/21
|
3/30/22
|
4/10/23
|
4/2/24
|
-
|
-
|
-
|
Last Close Price
11.96
CNY Average target price
14.7
CNY Spread / Average Target +22.91% Consensus |
1st Jan change
|
Capi.
|
---|
| -3.78% | 3.09B | | +25.61% | 661B | | +26.74% | 566B | | -6.64% | 352B | | +19.42% | 332B | | +3.49% | 283B | | +13.43% | 231B | | +4.71% | 200B | | -9.53% | 195B | | -4.75% | 145B |
Other Pharmaceuticals
|